Antiphospholipid syndrome
Antiphospholipid syndrome is an autoimmune systemic disorder characterized by arterial, venous, or small vessel thrombosis and/or recurrent early pregnancy loss, fetal loss, or pregnancy morbidity in the setting of documented persistent antiphospholipid antibodies that include the lupus anticoagulan...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Sammaritano, Lisa R. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020transfer abstract |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Mercury pollution in Wuchuan mercury mining area, Guizhou, Southwestern China: The impacts from large scale and artisanal mercury mining - 2012transfer abstract, London [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:34 ; year:2020 ; number:1 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.berh.2019.101463 |
|---|
| Katalog-ID: |
ELV050614347 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV050614347 | ||
| 003 | DE-627 | ||
| 005 | 20230626030856.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200625s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.berh.2019.101463 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001035.pica |
| 035 | |a (DE-627)ELV050614347 | ||
| 035 | |a (ELSEVIER)S1521-6942(19)30159-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 690 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 600 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.73 |2 bkl | ||
| 100 | 1 | |a Sammaritano, Lisa R. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antiphospholipid syndrome |
| 264 | 1 | |c 2020transfer abstract | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Antiphospholipid syndrome is an autoimmune systemic disorder characterized by arterial, venous, or small vessel thrombosis and/or recurrent early pregnancy loss, fetal loss, or pregnancy morbidity in the setting of documented persistent antiphospholipid antibodies that include the lupus anticoagulant, or moderate-high titer anticardiolipin, or anti-β2Glycoprotein I antibodies. Associated clinical manifestations include livedo reticularis, cutaneous ulcerations, thrombocytopenia, hemolytic anemia, valvular heart disease, and nephropathy. The degree of risk associated with antiphospholipid antibody depends on the characteristics of the antiphospholipid antibody profile and on the presence of additional thrombotic risk factors. Current standard treatment for unprovoked thrombosis is long-term warfarin or other vitamin K antagonist therapy. Treatment to prevent recurrent obstetric complications is low-dose aspirin and prophylactic heparin, usually low-molecular-weight heparin. Optimal treatment for standard therapy failures or for certain nonthrombotic manifestations is uncertain, although nonanticoagulation therapies that address multiple demonstrated mechanisms of disease are being explored. | ||
| 520 | |a Antiphospholipid syndrome is an autoimmune systemic disorder characterized by arterial, venous, or small vessel thrombosis and/or recurrent early pregnancy loss, fetal loss, or pregnancy morbidity in the setting of documented persistent antiphospholipid antibodies that include the lupus anticoagulant, or moderate-high titer anticardiolipin, or anti-β2Glycoprotein I antibodies. Associated clinical manifestations include livedo reticularis, cutaneous ulcerations, thrombocytopenia, hemolytic anemia, valvular heart disease, and nephropathy. The degree of risk associated with antiphospholipid antibody depends on the characteristics of the antiphospholipid antibody profile and on the presence of additional thrombotic risk factors. Current standard treatment for unprovoked thrombosis is long-term warfarin or other vitamin K antagonist therapy. Treatment to prevent recurrent obstetric complications is low-dose aspirin and prophylactic heparin, usually low-molecular-weight heparin. Optimal treatment for standard therapy failures or for certain nonthrombotic manifestations is uncertain, although nonanticoagulation therapies that address multiple demonstrated mechanisms of disease are being explored. | ||
| 650 | 7 | |a Anti-β2Glycoprotein I antibody |2 Elsevier | |
| 650 | 7 | |a Anticardiolipin antibody |2 Elsevier | |
| 650 | 7 | |a Thrombosis |2 Elsevier | |
| 650 | 7 | |a Antiphospholipid syndrome |2 Elsevier | |
| 650 | 7 | |a Lupus anticoagulant |2 Elsevier | |
| 650 | 7 | |a Pregnancy loss |2 Elsevier | |
| 773 | 0 | 8 | |i Enthalten in |n Baillière Tindall |t Mercury pollution in Wuchuan mercury mining area, Guizhou, Southwestern China: The impacts from large scale and artisanal mercury mining |d 2012transfer abstract |g London [u.a.] |w (DE-627)ELV026205912 |
| 773 | 1 | 8 | |g volume:34 |g year:2020 |g number:1 |g pages:0 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.berh.2019.101463 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.73 |j Geomedizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 34 |j 2020 |e 1 |h 0 | ||
| author_variant |
l r s lr lrs |
|---|---|
| matchkey_str |
sammaritanolisar:2020----:nihshlpdy |
| hierarchy_sort_str |
2020transfer abstract |
| bklnumber |
44.73 |
| publishDate |
2020 |
| allfields |
10.1016/j.berh.2019.101463 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001035.pica (DE-627)ELV050614347 (ELSEVIER)S1521-6942(19)30159-7 DE-627 ger DE-627 rakwb eng 690 VZ 610 VZ 600 VZ 610 VZ 44.73 bkl Sammaritano, Lisa R. verfasserin aut Antiphospholipid syndrome 2020transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Antiphospholipid syndrome is an autoimmune systemic disorder characterized by arterial, venous, or small vessel thrombosis and/or recurrent early pregnancy loss, fetal loss, or pregnancy morbidity in the setting of documented persistent antiphospholipid antibodies that include the lupus anticoagulant, or moderate-high titer anticardiolipin, or anti-β2Glycoprotein I antibodies. Associated clinical manifestations include livedo reticularis, cutaneous ulcerations, thrombocytopenia, hemolytic anemia, valvular heart disease, and nephropathy. The degree of risk associated with antiphospholipid antibody depends on the characteristics of the antiphospholipid antibody profile and on the presence of additional thrombotic risk factors. Current standard treatment for unprovoked thrombosis is long-term warfarin or other vitamin K antagonist therapy. Treatment to prevent recurrent obstetric complications is low-dose aspirin and prophylactic heparin, usually low-molecular-weight heparin. Optimal treatment for standard therapy failures or for certain nonthrombotic manifestations is uncertain, although nonanticoagulation therapies that address multiple demonstrated mechanisms of disease are being explored. Antiphospholipid syndrome is an autoimmune systemic disorder characterized by arterial, venous, or small vessel thrombosis and/or recurrent early pregnancy loss, fetal loss, or pregnancy morbidity in the setting of documented persistent antiphospholipid antibodies that include the lupus anticoagulant, or moderate-high titer anticardiolipin, or anti-β2Glycoprotein I antibodies. Associated clinical manifestations include livedo reticularis, cutaneous ulcerations, thrombocytopenia, hemolytic anemia, valvular heart disease, and nephropathy. The degree of risk associated with antiphospholipid antibody depends on the characteristics of the antiphospholipid antibody profile and on the presence of additional thrombotic risk factors. Current standard treatment for unprovoked thrombosis is long-term warfarin or other vitamin K antagonist therapy. Treatment to prevent recurrent obstetric complications is low-dose aspirin and prophylactic heparin, usually low-molecular-weight heparin. Optimal treatment for standard therapy failures or for certain nonthrombotic manifestations is uncertain, although nonanticoagulation therapies that address multiple demonstrated mechanisms of disease are being explored. Anti-β2Glycoprotein I antibody Elsevier Anticardiolipin antibody Elsevier Thrombosis Elsevier Antiphospholipid syndrome Elsevier Lupus anticoagulant Elsevier Pregnancy loss Elsevier Enthalten in Baillière Tindall Mercury pollution in Wuchuan mercury mining area, Guizhou, Southwestern China: The impacts from large scale and artisanal mercury mining 2012transfer abstract London [u.a.] (DE-627)ELV026205912 volume:34 year:2020 number:1 pages:0 https://doi.org/10.1016/j.berh.2019.101463 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.73 Geomedizin VZ AR 34 2020 1 0 |
| spelling |
10.1016/j.berh.2019.101463 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001035.pica (DE-627)ELV050614347 (ELSEVIER)S1521-6942(19)30159-7 DE-627 ger DE-627 rakwb eng 690 VZ 610 VZ 600 VZ 610 VZ 44.73 bkl Sammaritano, Lisa R. verfasserin aut Antiphospholipid syndrome 2020transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Antiphospholipid syndrome is an autoimmune systemic disorder characterized by arterial, venous, or small vessel thrombosis and/or recurrent early pregnancy loss, fetal loss, or pregnancy morbidity in the setting of documented persistent antiphospholipid antibodies that include the lupus anticoagulant, or moderate-high titer anticardiolipin, or anti-β2Glycoprotein I antibodies. Associated clinical manifestations include livedo reticularis, cutaneous ulcerations, thrombocytopenia, hemolytic anemia, valvular heart disease, and nephropathy. The degree of risk associated with antiphospholipid antibody depends on the characteristics of the antiphospholipid antibody profile and on the presence of additional thrombotic risk factors. Current standard treatment for unprovoked thrombosis is long-term warfarin or other vitamin K antagonist therapy. Treatment to prevent recurrent obstetric complications is low-dose aspirin and prophylactic heparin, usually low-molecular-weight heparin. Optimal treatment for standard therapy failures or for certain nonthrombotic manifestations is uncertain, although nonanticoagulation therapies that address multiple demonstrated mechanisms of disease are being explored. Antiphospholipid syndrome is an autoimmune systemic disorder characterized by arterial, venous, or small vessel thrombosis and/or recurrent early pregnancy loss, fetal loss, or pregnancy morbidity in the setting of documented persistent antiphospholipid antibodies that include the lupus anticoagulant, or moderate-high titer anticardiolipin, or anti-β2Glycoprotein I antibodies. Associated clinical manifestations include livedo reticularis, cutaneous ulcerations, thrombocytopenia, hemolytic anemia, valvular heart disease, and nephropathy. The degree of risk associated with antiphospholipid antibody depends on the characteristics of the antiphospholipid antibody profile and on the presence of additional thrombotic risk factors. Current standard treatment for unprovoked thrombosis is long-term warfarin or other vitamin K antagonist therapy. Treatment to prevent recurrent obstetric complications is low-dose aspirin and prophylactic heparin, usually low-molecular-weight heparin. Optimal treatment for standard therapy failures or for certain nonthrombotic manifestations is uncertain, although nonanticoagulation therapies that address multiple demonstrated mechanisms of disease are being explored. Anti-β2Glycoprotein I antibody Elsevier Anticardiolipin antibody Elsevier Thrombosis Elsevier Antiphospholipid syndrome Elsevier Lupus anticoagulant Elsevier Pregnancy loss Elsevier Enthalten in Baillière Tindall Mercury pollution in Wuchuan mercury mining area, Guizhou, Southwestern China: The impacts from large scale and artisanal mercury mining 2012transfer abstract London [u.a.] (DE-627)ELV026205912 volume:34 year:2020 number:1 pages:0 https://doi.org/10.1016/j.berh.2019.101463 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.73 Geomedizin VZ AR 34 2020 1 0 |
| allfields_unstemmed |
10.1016/j.berh.2019.101463 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001035.pica (DE-627)ELV050614347 (ELSEVIER)S1521-6942(19)30159-7 DE-627 ger DE-627 rakwb eng 690 VZ 610 VZ 600 VZ 610 VZ 44.73 bkl Sammaritano, Lisa R. verfasserin aut Antiphospholipid syndrome 2020transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Antiphospholipid syndrome is an autoimmune systemic disorder characterized by arterial, venous, or small vessel thrombosis and/or recurrent early pregnancy loss, fetal loss, or pregnancy morbidity in the setting of documented persistent antiphospholipid antibodies that include the lupus anticoagulant, or moderate-high titer anticardiolipin, or anti-β2Glycoprotein I antibodies. Associated clinical manifestations include livedo reticularis, cutaneous ulcerations, thrombocytopenia, hemolytic anemia, valvular heart disease, and nephropathy. The degree of risk associated with antiphospholipid antibody depends on the characteristics of the antiphospholipid antibody profile and on the presence of additional thrombotic risk factors. Current standard treatment for unprovoked thrombosis is long-term warfarin or other vitamin K antagonist therapy. Treatment to prevent recurrent obstetric complications is low-dose aspirin and prophylactic heparin, usually low-molecular-weight heparin. Optimal treatment for standard therapy failures or for certain nonthrombotic manifestations is uncertain, although nonanticoagulation therapies that address multiple demonstrated mechanisms of disease are being explored. Antiphospholipid syndrome is an autoimmune systemic disorder characterized by arterial, venous, or small vessel thrombosis and/or recurrent early pregnancy loss, fetal loss, or pregnancy morbidity in the setting of documented persistent antiphospholipid antibodies that include the lupus anticoagulant, or moderate-high titer anticardiolipin, or anti-β2Glycoprotein I antibodies. Associated clinical manifestations include livedo reticularis, cutaneous ulcerations, thrombocytopenia, hemolytic anemia, valvular heart disease, and nephropathy. The degree of risk associated with antiphospholipid antibody depends on the characteristics of the antiphospholipid antibody profile and on the presence of additional thrombotic risk factors. Current standard treatment for unprovoked thrombosis is long-term warfarin or other vitamin K antagonist therapy. Treatment to prevent recurrent obstetric complications is low-dose aspirin and prophylactic heparin, usually low-molecular-weight heparin. Optimal treatment for standard therapy failures or for certain nonthrombotic manifestations is uncertain, although nonanticoagulation therapies that address multiple demonstrated mechanisms of disease are being explored. Anti-β2Glycoprotein I antibody Elsevier Anticardiolipin antibody Elsevier Thrombosis Elsevier Antiphospholipid syndrome Elsevier Lupus anticoagulant Elsevier Pregnancy loss Elsevier Enthalten in Baillière Tindall Mercury pollution in Wuchuan mercury mining area, Guizhou, Southwestern China: The impacts from large scale and artisanal mercury mining 2012transfer abstract London [u.a.] (DE-627)ELV026205912 volume:34 year:2020 number:1 pages:0 https://doi.org/10.1016/j.berh.2019.101463 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.73 Geomedizin VZ AR 34 2020 1 0 |
| allfieldsGer |
10.1016/j.berh.2019.101463 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001035.pica (DE-627)ELV050614347 (ELSEVIER)S1521-6942(19)30159-7 DE-627 ger DE-627 rakwb eng 690 VZ 610 VZ 600 VZ 610 VZ 44.73 bkl Sammaritano, Lisa R. verfasserin aut Antiphospholipid syndrome 2020transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Antiphospholipid syndrome is an autoimmune systemic disorder characterized by arterial, venous, or small vessel thrombosis and/or recurrent early pregnancy loss, fetal loss, or pregnancy morbidity in the setting of documented persistent antiphospholipid antibodies that include the lupus anticoagulant, or moderate-high titer anticardiolipin, or anti-β2Glycoprotein I antibodies. Associated clinical manifestations include livedo reticularis, cutaneous ulcerations, thrombocytopenia, hemolytic anemia, valvular heart disease, and nephropathy. The degree of risk associated with antiphospholipid antibody depends on the characteristics of the antiphospholipid antibody profile and on the presence of additional thrombotic risk factors. Current standard treatment for unprovoked thrombosis is long-term warfarin or other vitamin K antagonist therapy. Treatment to prevent recurrent obstetric complications is low-dose aspirin and prophylactic heparin, usually low-molecular-weight heparin. Optimal treatment for standard therapy failures or for certain nonthrombotic manifestations is uncertain, although nonanticoagulation therapies that address multiple demonstrated mechanisms of disease are being explored. Antiphospholipid syndrome is an autoimmune systemic disorder characterized by arterial, venous, or small vessel thrombosis and/or recurrent early pregnancy loss, fetal loss, or pregnancy morbidity in the setting of documented persistent antiphospholipid antibodies that include the lupus anticoagulant, or moderate-high titer anticardiolipin, or anti-β2Glycoprotein I antibodies. Associated clinical manifestations include livedo reticularis, cutaneous ulcerations, thrombocytopenia, hemolytic anemia, valvular heart disease, and nephropathy. The degree of risk associated with antiphospholipid antibody depends on the characteristics of the antiphospholipid antibody profile and on the presence of additional thrombotic risk factors. Current standard treatment for unprovoked thrombosis is long-term warfarin or other vitamin K antagonist therapy. Treatment to prevent recurrent obstetric complications is low-dose aspirin and prophylactic heparin, usually low-molecular-weight heparin. Optimal treatment for standard therapy failures or for certain nonthrombotic manifestations is uncertain, although nonanticoagulation therapies that address multiple demonstrated mechanisms of disease are being explored. Anti-β2Glycoprotein I antibody Elsevier Anticardiolipin antibody Elsevier Thrombosis Elsevier Antiphospholipid syndrome Elsevier Lupus anticoagulant Elsevier Pregnancy loss Elsevier Enthalten in Baillière Tindall Mercury pollution in Wuchuan mercury mining area, Guizhou, Southwestern China: The impacts from large scale and artisanal mercury mining 2012transfer abstract London [u.a.] (DE-627)ELV026205912 volume:34 year:2020 number:1 pages:0 https://doi.org/10.1016/j.berh.2019.101463 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.73 Geomedizin VZ AR 34 2020 1 0 |
| allfieldsSound |
10.1016/j.berh.2019.101463 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001035.pica (DE-627)ELV050614347 (ELSEVIER)S1521-6942(19)30159-7 DE-627 ger DE-627 rakwb eng 690 VZ 610 VZ 600 VZ 610 VZ 44.73 bkl Sammaritano, Lisa R. verfasserin aut Antiphospholipid syndrome 2020transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Antiphospholipid syndrome is an autoimmune systemic disorder characterized by arterial, venous, or small vessel thrombosis and/or recurrent early pregnancy loss, fetal loss, or pregnancy morbidity in the setting of documented persistent antiphospholipid antibodies that include the lupus anticoagulant, or moderate-high titer anticardiolipin, or anti-β2Glycoprotein I antibodies. Associated clinical manifestations include livedo reticularis, cutaneous ulcerations, thrombocytopenia, hemolytic anemia, valvular heart disease, and nephropathy. The degree of risk associated with antiphospholipid antibody depends on the characteristics of the antiphospholipid antibody profile and on the presence of additional thrombotic risk factors. Current standard treatment for unprovoked thrombosis is long-term warfarin or other vitamin K antagonist therapy. Treatment to prevent recurrent obstetric complications is low-dose aspirin and prophylactic heparin, usually low-molecular-weight heparin. Optimal treatment for standard therapy failures or for certain nonthrombotic manifestations is uncertain, although nonanticoagulation therapies that address multiple demonstrated mechanisms of disease are being explored. Antiphospholipid syndrome is an autoimmune systemic disorder characterized by arterial, venous, or small vessel thrombosis and/or recurrent early pregnancy loss, fetal loss, or pregnancy morbidity in the setting of documented persistent antiphospholipid antibodies that include the lupus anticoagulant, or moderate-high titer anticardiolipin, or anti-β2Glycoprotein I antibodies. Associated clinical manifestations include livedo reticularis, cutaneous ulcerations, thrombocytopenia, hemolytic anemia, valvular heart disease, and nephropathy. The degree of risk associated with antiphospholipid antibody depends on the characteristics of the antiphospholipid antibody profile and on the presence of additional thrombotic risk factors. Current standard treatment for unprovoked thrombosis is long-term warfarin or other vitamin K antagonist therapy. Treatment to prevent recurrent obstetric complications is low-dose aspirin and prophylactic heparin, usually low-molecular-weight heparin. Optimal treatment for standard therapy failures or for certain nonthrombotic manifestations is uncertain, although nonanticoagulation therapies that address multiple demonstrated mechanisms of disease are being explored. Anti-β2Glycoprotein I antibody Elsevier Anticardiolipin antibody Elsevier Thrombosis Elsevier Antiphospholipid syndrome Elsevier Lupus anticoagulant Elsevier Pregnancy loss Elsevier Enthalten in Baillière Tindall Mercury pollution in Wuchuan mercury mining area, Guizhou, Southwestern China: The impacts from large scale and artisanal mercury mining 2012transfer abstract London [u.a.] (DE-627)ELV026205912 volume:34 year:2020 number:1 pages:0 https://doi.org/10.1016/j.berh.2019.101463 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.73 Geomedizin VZ AR 34 2020 1 0 |
| language |
English |
| source |
Enthalten in Mercury pollution in Wuchuan mercury mining area, Guizhou, Southwestern China: The impacts from large scale and artisanal mercury mining London [u.a.] volume:34 year:2020 number:1 pages:0 |
| sourceStr |
Enthalten in Mercury pollution in Wuchuan mercury mining area, Guizhou, Southwestern China: The impacts from large scale and artisanal mercury mining London [u.a.] volume:34 year:2020 number:1 pages:0 |
| format_phy_str_mv |
Article |
| bklname |
Geomedizin |
| institution |
findex.gbv.de |
| topic_facet |
Anti-β2Glycoprotein I antibody Anticardiolipin antibody Thrombosis Antiphospholipid syndrome Lupus anticoagulant Pregnancy loss |
| dewey-raw |
690 |
| isfreeaccess_bool |
false |
| container_title |
Mercury pollution in Wuchuan mercury mining area, Guizhou, Southwestern China: The impacts from large scale and artisanal mercury mining |
| authorswithroles_txt_mv |
Sammaritano, Lisa R. @@aut@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
ELV026205912 |
| dewey-sort |
3690 |
| id |
ELV050614347 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV050614347</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626030856.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200625s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.berh.2019.101463</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001035.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV050614347</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1521-6942(19)30159-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">600</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.73</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sammaritano, Lisa R.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Antiphospholipid syndrome</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Antiphospholipid syndrome is an autoimmune systemic disorder characterized by arterial, venous, or small vessel thrombosis and/or recurrent early pregnancy loss, fetal loss, or pregnancy morbidity in the setting of documented persistent antiphospholipid antibodies that include the lupus anticoagulant, or moderate-high titer anticardiolipin, or anti-β2Glycoprotein I antibodies. Associated clinical manifestations include livedo reticularis, cutaneous ulcerations, thrombocytopenia, hemolytic anemia, valvular heart disease, and nephropathy. The degree of risk associated with antiphospholipid antibody depends on the characteristics of the antiphospholipid antibody profile and on the presence of additional thrombotic risk factors. Current standard treatment for unprovoked thrombosis is long-term warfarin or other vitamin K antagonist therapy. Treatment to prevent recurrent obstetric complications is low-dose aspirin and prophylactic heparin, usually low-molecular-weight heparin. Optimal treatment for standard therapy failures or for certain nonthrombotic manifestations is uncertain, although nonanticoagulation therapies that address multiple demonstrated mechanisms of disease are being explored.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Antiphospholipid syndrome is an autoimmune systemic disorder characterized by arterial, venous, or small vessel thrombosis and/or recurrent early pregnancy loss, fetal loss, or pregnancy morbidity in the setting of documented persistent antiphospholipid antibodies that include the lupus anticoagulant, or moderate-high titer anticardiolipin, or anti-β2Glycoprotein I antibodies. Associated clinical manifestations include livedo reticularis, cutaneous ulcerations, thrombocytopenia, hemolytic anemia, valvular heart disease, and nephropathy. The degree of risk associated with antiphospholipid antibody depends on the characteristics of the antiphospholipid antibody profile and on the presence of additional thrombotic risk factors. Current standard treatment for unprovoked thrombosis is long-term warfarin or other vitamin K antagonist therapy. Treatment to prevent recurrent obstetric complications is low-dose aspirin and prophylactic heparin, usually low-molecular-weight heparin. Optimal treatment for standard therapy failures or for certain nonthrombotic manifestations is uncertain, although nonanticoagulation therapies that address multiple demonstrated mechanisms of disease are being explored.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Anti-β2Glycoprotein I antibody</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Anticardiolipin antibody</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Thrombosis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antiphospholipid syndrome</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Lupus anticoagulant</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pregnancy loss</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Baillière Tindall</subfield><subfield code="t">Mercury pollution in Wuchuan mercury mining area, Guizhou, Southwestern China: The impacts from large scale and artisanal mercury mining</subfield><subfield code="d">2012transfer abstract</subfield><subfield code="g">London [u.a.]</subfield><subfield code="w">(DE-627)ELV026205912</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:34</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.berh.2019.101463</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.73</subfield><subfield code="j">Geomedizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">34</subfield><subfield code="j">2020</subfield><subfield code="e">1</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| author |
Sammaritano, Lisa R. |
| spellingShingle |
Sammaritano, Lisa R. ddc 690 ddc 610 ddc 600 bkl 44.73 Elsevier Anti-β2Glycoprotein I antibody Elsevier Anticardiolipin antibody Elsevier Thrombosis Elsevier Antiphospholipid syndrome Elsevier Lupus anticoagulant Elsevier Pregnancy loss Antiphospholipid syndrome |
| authorStr |
Sammaritano, Lisa R. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV026205912 |
| format |
electronic Article |
| dewey-ones |
690 - Buildings 610 - Medicine & health 600 - Technology |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
690 VZ 610 VZ 600 VZ 44.73 bkl Antiphospholipid syndrome Anti-β2Glycoprotein I antibody Elsevier Anticardiolipin antibody Elsevier Thrombosis Elsevier Antiphospholipid syndrome Elsevier Lupus anticoagulant Elsevier Pregnancy loss Elsevier |
| topic |
ddc 690 ddc 610 ddc 600 bkl 44.73 Elsevier Anti-β2Glycoprotein I antibody Elsevier Anticardiolipin antibody Elsevier Thrombosis Elsevier Antiphospholipid syndrome Elsevier Lupus anticoagulant Elsevier Pregnancy loss |
| topic_unstemmed |
ddc 690 ddc 610 ddc 600 bkl 44.73 Elsevier Anti-β2Glycoprotein I antibody Elsevier Anticardiolipin antibody Elsevier Thrombosis Elsevier Antiphospholipid syndrome Elsevier Lupus anticoagulant Elsevier Pregnancy loss |
| topic_browse |
ddc 690 ddc 610 ddc 600 bkl 44.73 Elsevier Anti-β2Glycoprotein I antibody Elsevier Anticardiolipin antibody Elsevier Thrombosis Elsevier Antiphospholipid syndrome Elsevier Lupus anticoagulant Elsevier Pregnancy loss |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| hierarchy_parent_title |
Mercury pollution in Wuchuan mercury mining area, Guizhou, Southwestern China: The impacts from large scale and artisanal mercury mining |
| hierarchy_parent_id |
ELV026205912 |
| dewey-tens |
690 - Building & construction 610 - Medicine & health 600 - Technology |
| hierarchy_top_title |
Mercury pollution in Wuchuan mercury mining area, Guizhou, Southwestern China: The impacts from large scale and artisanal mercury mining |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV026205912 |
| title |
Antiphospholipid syndrome |
| ctrlnum |
(DE-627)ELV050614347 (ELSEVIER)S1521-6942(19)30159-7 |
| title_full |
Antiphospholipid syndrome |
| author_sort |
Sammaritano, Lisa R. |
| journal |
Mercury pollution in Wuchuan mercury mining area, Guizhou, Southwestern China: The impacts from large scale and artisanal mercury mining |
| journalStr |
Mercury pollution in Wuchuan mercury mining area, Guizhou, Southwestern China: The impacts from large scale and artisanal mercury mining |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Sammaritano, Lisa R. |
| container_volume |
34 |
| class |
690 VZ 610 VZ 600 VZ 44.73 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Sammaritano, Lisa R. |
| doi_str_mv |
10.1016/j.berh.2019.101463 |
| dewey-full |
690 610 600 |
| title_sort |
antiphospholipid syndrome |
| title_auth |
Antiphospholipid syndrome |
| abstract |
Antiphospholipid syndrome is an autoimmune systemic disorder characterized by arterial, venous, or small vessel thrombosis and/or recurrent early pregnancy loss, fetal loss, or pregnancy morbidity in the setting of documented persistent antiphospholipid antibodies that include the lupus anticoagulant, or moderate-high titer anticardiolipin, or anti-β2Glycoprotein I antibodies. Associated clinical manifestations include livedo reticularis, cutaneous ulcerations, thrombocytopenia, hemolytic anemia, valvular heart disease, and nephropathy. The degree of risk associated with antiphospholipid antibody depends on the characteristics of the antiphospholipid antibody profile and on the presence of additional thrombotic risk factors. Current standard treatment for unprovoked thrombosis is long-term warfarin or other vitamin K antagonist therapy. Treatment to prevent recurrent obstetric complications is low-dose aspirin and prophylactic heparin, usually low-molecular-weight heparin. Optimal treatment for standard therapy failures or for certain nonthrombotic manifestations is uncertain, although nonanticoagulation therapies that address multiple demonstrated mechanisms of disease are being explored. |
| abstractGer |
Antiphospholipid syndrome is an autoimmune systemic disorder characterized by arterial, venous, or small vessel thrombosis and/or recurrent early pregnancy loss, fetal loss, or pregnancy morbidity in the setting of documented persistent antiphospholipid antibodies that include the lupus anticoagulant, or moderate-high titer anticardiolipin, or anti-β2Glycoprotein I antibodies. Associated clinical manifestations include livedo reticularis, cutaneous ulcerations, thrombocytopenia, hemolytic anemia, valvular heart disease, and nephropathy. The degree of risk associated with antiphospholipid antibody depends on the characteristics of the antiphospholipid antibody profile and on the presence of additional thrombotic risk factors. Current standard treatment for unprovoked thrombosis is long-term warfarin or other vitamin K antagonist therapy. Treatment to prevent recurrent obstetric complications is low-dose aspirin and prophylactic heparin, usually low-molecular-weight heparin. Optimal treatment for standard therapy failures or for certain nonthrombotic manifestations is uncertain, although nonanticoagulation therapies that address multiple demonstrated mechanisms of disease are being explored. |
| abstract_unstemmed |
Antiphospholipid syndrome is an autoimmune systemic disorder characterized by arterial, venous, or small vessel thrombosis and/or recurrent early pregnancy loss, fetal loss, or pregnancy morbidity in the setting of documented persistent antiphospholipid antibodies that include the lupus anticoagulant, or moderate-high titer anticardiolipin, or anti-β2Glycoprotein I antibodies. Associated clinical manifestations include livedo reticularis, cutaneous ulcerations, thrombocytopenia, hemolytic anemia, valvular heart disease, and nephropathy. The degree of risk associated with antiphospholipid antibody depends on the characteristics of the antiphospholipid antibody profile and on the presence of additional thrombotic risk factors. Current standard treatment for unprovoked thrombosis is long-term warfarin or other vitamin K antagonist therapy. Treatment to prevent recurrent obstetric complications is low-dose aspirin and prophylactic heparin, usually low-molecular-weight heparin. Optimal treatment for standard therapy failures or for certain nonthrombotic manifestations is uncertain, although nonanticoagulation therapies that address multiple demonstrated mechanisms of disease are being explored. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
1 |
| title_short |
Antiphospholipid syndrome |
| url |
https://doi.org/10.1016/j.berh.2019.101463 |
| remote_bool |
true |
| ppnlink |
ELV026205912 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1016/j.berh.2019.101463 |
| up_date |
2024-07-06T18:01:00.583Z |
| _version_ |
1803853612275728384 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV050614347</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626030856.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200625s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.berh.2019.101463</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001035.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV050614347</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1521-6942(19)30159-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">600</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.73</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sammaritano, Lisa R.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Antiphospholipid syndrome</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Antiphospholipid syndrome is an autoimmune systemic disorder characterized by arterial, venous, or small vessel thrombosis and/or recurrent early pregnancy loss, fetal loss, or pregnancy morbidity in the setting of documented persistent antiphospholipid antibodies that include the lupus anticoagulant, or moderate-high titer anticardiolipin, or anti-β2Glycoprotein I antibodies. Associated clinical manifestations include livedo reticularis, cutaneous ulcerations, thrombocytopenia, hemolytic anemia, valvular heart disease, and nephropathy. The degree of risk associated with antiphospholipid antibody depends on the characteristics of the antiphospholipid antibody profile and on the presence of additional thrombotic risk factors. Current standard treatment for unprovoked thrombosis is long-term warfarin or other vitamin K antagonist therapy. Treatment to prevent recurrent obstetric complications is low-dose aspirin and prophylactic heparin, usually low-molecular-weight heparin. Optimal treatment for standard therapy failures or for certain nonthrombotic manifestations is uncertain, although nonanticoagulation therapies that address multiple demonstrated mechanisms of disease are being explored.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Antiphospholipid syndrome is an autoimmune systemic disorder characterized by arterial, venous, or small vessel thrombosis and/or recurrent early pregnancy loss, fetal loss, or pregnancy morbidity in the setting of documented persistent antiphospholipid antibodies that include the lupus anticoagulant, or moderate-high titer anticardiolipin, or anti-β2Glycoprotein I antibodies. Associated clinical manifestations include livedo reticularis, cutaneous ulcerations, thrombocytopenia, hemolytic anemia, valvular heart disease, and nephropathy. The degree of risk associated with antiphospholipid antibody depends on the characteristics of the antiphospholipid antibody profile and on the presence of additional thrombotic risk factors. Current standard treatment for unprovoked thrombosis is long-term warfarin or other vitamin K antagonist therapy. Treatment to prevent recurrent obstetric complications is low-dose aspirin and prophylactic heparin, usually low-molecular-weight heparin. Optimal treatment for standard therapy failures or for certain nonthrombotic manifestations is uncertain, although nonanticoagulation therapies that address multiple demonstrated mechanisms of disease are being explored.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Anti-β2Glycoprotein I antibody</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Anticardiolipin antibody</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Thrombosis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antiphospholipid syndrome</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Lupus anticoagulant</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pregnancy loss</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Baillière Tindall</subfield><subfield code="t">Mercury pollution in Wuchuan mercury mining area, Guizhou, Southwestern China: The impacts from large scale and artisanal mercury mining</subfield><subfield code="d">2012transfer abstract</subfield><subfield code="g">London [u.a.]</subfield><subfield code="w">(DE-627)ELV026205912</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:34</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.berh.2019.101463</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.73</subfield><subfield code="j">Geomedizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">34</subfield><subfield code="j">2020</subfield><subfield code="e">1</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.4021015 |